Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

28.52 -0.43 (-1.49%)
Streaming Delayed Price Updated: 2:28 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 Next >
News headline image
This Biotech Stock Could Cure Your Portfolio's Pain ↗
A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive. 
Via The Motley Fool
News headline image
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Shows Strong Technical and Fundamental Momentum ↗
Arcuitis Biotherapeutics (ARQT) exemplifies a high-growth momentum stock in a confirmed technical uptrend, blending strong fundamentals with a robust price structure. 
Via Chartmill
News headline image
Why Shares in Arcutis Biotherapeutics Surged Again This Week ↗
The company continues to receive good news from the Food and Drug Administration. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For October 28, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest ↗
 
Via Benzinga
News headline image
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Strong Trend with High-Growth Momentum ↗
ARQT stock combines a strong Minervini Trend Template setup with explosive sales and earnings growth, creating a compelling high-growth momentum opportunity. 
Via Chartmill
News headline image
These stocks are moving in today's session ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Arcutis Q3 2025 Earnings Call Transcript ↗
Arcutis Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Top stock movements in today's session. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Falls Over 2%; PayPal Shares Spike Higher ↗
 
Via Benzinga
News headline image
Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today ↗
Arcutis Biotherapeutics had an excellent update for investors and its future looks bright. 
Via The Motley Fool
News headline image
Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. ↗
Arcutis Biotherapeutics smashed quarterly calls Tuesday and reported its first-ever positive net income. 
Via Investor's Business Daily
News headline image
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Reports Strong Q3 2025 Earnings Beat and Return to Profitability ↗
Arcutis (ARQT) Q3 2025 earnings crush estimates with a surprise profit. Revenue of $99.2M beats forecasts, driving the stock up 16% on strong ZORYVE demand. 
Via Chartmill
Topics Earnings
News headline image
Uncovering Potential: Arcutis Biotherapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Technical Strength with High Growth Momentum ↗
Discover ARQT stock, a top growth pick blending Minervini's strong trend template with explosive earnings and sales momentum for potential outperformance. 
Via Chartmill
News headline image
Top 5 Biotech Stocks With Strong Momentum ↗
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies. 
Via Benzinga
News headline image
3 Biotech Catalysts Present Major Opportunity ↗
Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further. 
Via MarketBeat
News headline image
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Fits the Minervini Trend Template with Strong Growth Momentum ↗
Discover how Arcutis Biotherapeutics (ARQT) fits Mark Minervini’s Trend Template with strong technicals, high growth momentum, and fast-improving earnings—ideal for growth investors. 
Via Chartmill
News headline image
Arcutis (ARQT) Q2 Revenue Soars 164% ↗
Via The Motley Fool
News headline image
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Beats Q2 2025 Revenue Estimates and Posts Narrower Loss Than Expected ↗
Arcutis Biotherapeutics (ARQT) beats Q2 2025 revenue and EPS estimates with $81.5M in sales, driven by strong ZORYVE demand. Shares rise post-earnings. 
Via Chartmill
News headline image
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis ↗
Arcutis will present five posters at RAD 2025 featuring long-term safety and efficacy data for Zoryve cream in children with eczema. 
Via Benzinga
News headline image
Analyst Expectations For Arcutis Biotherapeutics's Future ↗
 
Via Benzinga
News headline image
Would Mark Minervini consider ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) a top stock pick? ↗
A fundamental and technical analysis of (NASDAQ:ARQT): Is ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) suited for high growth investing? 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.